We use cookies for a better user experience. Read our Privacy Policy

I Agree

Radiopharmaceutical Theranostics Market Forecast Report, 2021-2031

Radiopharmaceutical Theranostics Market (Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and Others; Application: Oncology, Cardiology, and Others; Source: Nuclear Reactors and Cyclotrons; End User: Hospitals, Academic & Research Institutes, and Others; and Approach: Targeted Therapeutic [Rx] and Companion Diagnostic [DX]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Radio-labeled Analogs of Nuclear Medicine to Facilitate Antiviral COVID-19 Drug Development

The emergence of the COVID-19 outbreak has become a threat to the global health. This has compelled stakeholders in the radiopharmaceutical theranostics market to increase their R&D in nuclear medicine techniques that are found to be useful for functioning imaging of physiological processes at the cellular or molecular level. Companies are expanding in treatment approaches based on targeted delivery of therapeutic radionuclides.

Advancements in radiolabeling methods can significantly improve the accessibility of radiopharmaceuticals for in vivo molecular imaging or targeted radionuclide therapy. Such trends are anticipated to boost the growth of the radiopharmaceutical theranostics market during the ongoing pandemic. Stakeholders are expected to collaborate with researchers to describe how radio-labeled analogs of nuclear medicine could facilitate antiviral drug development.

radiopharmaceutical theranostics market infographic

To know the scope of our report Get a Sample on Radiopharmaceutical Theranostics Market

Integrating PET & MRI Modalities Challenging Due to Possible Interference

Nuclear medicines have led to the popularity of radiopharmaceuticals that carry the ability to destroy specific diseased cells with high-energy-emitting radionuclides. However, it has been found that integrating positron emission tomography (PET) and MRI (magnetic resonance imaging) modalities is challenging, as there is a possibility for interference between both the modalities. Hence, stakeholders are integrating PET detectors and MR scanners to obtain PET and MR images simultaneously.

Companies in the radiopharmaceutical theranostics market are increasing the availability of radioactive medicines through oral, intravenous, and interstitial route to diagnose malignancy. The high prevalence of cancer is acting as a key growth driver of the radiopharmaceutical theranostics market, as radioactive medicines have the ability to destroy cancerous cells by emitting radiation when it reaches the target cell.

Get a glimpse of the in-depth analysis through our Report Brochure

U.S., Europe Attract Investments to Increase R&D in Radiopharmaceuticals

Radiopharmaceuticals are generating major oncology deals globally. A €182 Mn IPO was announced in June 2020, where the U.S.-based Fusion Pharma was recently recruited by pharma giant AstraZeneca to co-develop radiotherapies for cancer. Apart from major investments taking place in the U.S., stakeholders in the radiopharmaceutical theranostics market are witnessing a high level of interest and activity in Europe and the Far East. In September 2020, the Belgian company Camel-IDS rebranded as Precirix has advanced its lead candidate radiopharmaceutical into phase I/II.

Since responses with radiopharmaceutical agents typically do not require many months of therapy, it is being preferred over chemotherapy and immunotherapy. Radioactive iodine is emerging as the gold standard to image the spread of thyroid tumors.

Cerenkov Radiation Energy Approach Targets Cancer Cells Effectively

In a research presented at the Society of Nuclear Medicine and Molecular Imaging’s 2021 Virtual Annual Meeting, a novel cancer treatment approach is being publicized for utilizing the Cerenkov radiation energy to target and destroy cancer cells more effectively. Companies in the radiopharmaceutical theranostics market are taking cues from such insights to use light from decaying radiopharmaceuticals, known as Cerenkov luminescence, as an energy source to activate semiconducting polymer nanoparticles that kill cancer cells.

Cerenkov luminescence is being proposed as an internal energy source for cancer therapy in the radiopharmaceutical theranostics market. This light source can be amplified with semiconducting polymers, which greatly increases its potential to target and destroy cancer cells.

Growing Incidence of Non-communicable Diseases in Pakistan Create Revenue Opportunities

The Nuclear Medicine Oncology and Radiotherapy Centre (INOR) in Abbottabad and the Institute of Nuclear Medicine and Oncology (INMOL) in Lahore, Pakistan, are now developing novel radiopharmaceuticals for use in theranostic procedures, using equipment and training provided through the IAEA’s technical cooperation (TC) program. This is evident since non-communicable diseases such as cardiac dysfunction, cancer, and neurological disorders are concerning national health authorities in the country.

Since the incidence of non-communicable diseases is estimated to double in the upcoming years in Pakistan, theranostic interventions are gaining popularity for accurate diagnosis of cancer in the radiopharmaceutical theranostics market.

radiopharmaceutical theranostics market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Based on the continuing threat by the ongoing coronaviruses pandemic and other pathogens, it is anticipated that nuclear medicines hold strong potential in the development of antiviral drug and treatment. The radiopharmaceutical theranostics market is projected to expand at a robust CAGR of 11% from 2021 to 2031. The photodynamic therapy helps activate nanomaterials for the cancer therapy. However, this technique is limited by the ability of external light to penetrate tissues. Hence, companies should increase their R&D in Cerenkov luminescence, which is spontaneously produced from certain radiopharmaceuticals as the decay in the body. This technique has been proposed as an internal energy source for the cancer therapy.

Radiopharmaceutical Theranostics Market: Overview

  • Nuclear medicine imaging is primarily based on the principle of using radioactive isotopes attached to specific molecules (i.e., radiopharmaceutical agents or radiotracers) to examine key biologic processes, including disease pathophysiology. These drugs can be administered orally (in tablet form), intravenously (into a patient's vein), or interstitially (via the skin) (inserted into a cavity in the body). Radiopharmacology is a specialty of radiation treatment; however, regulations require that the drugs be delivered by a radiopharmacist, a medical professional who specializes in nuclear medicine.
  • Every radiopharmaceutical is designed to travel to a different location in the body. When it reaches its location, it will release radioactive substances that will kill the tumor cells. Researchers have found radiopharmaceuticals that can target various malignancies such as colorectal cancer, prostate cancer, heart disease, thyroid cancer, etc.
  • After decades of neglect by big pharma, radiopharmaceuticals are now creating significant cancer deals across the globe. This could result in an increase in cancer drugs that can be used as both therapies and diagnostics, known as ‘theranostics‘.
  • Recently, there has been significant activity from companies developing drugs employing radioactivity to destroy tumors. Telix Pharmaceuticals, an Australia-based company, has licensed its portfolio to China Grand Pharma for EUR 242 Mn (AUD 400 Mn).
  • Vect-Horus is a newcomer to the theranostics field, primarily supplying peptide vectors for drug delivery. With a recent EUR 6.7 Mn fundraising, the company is ready to begin phase I development of a theranostics glioblastoma medication with the U.S.-based partner RadioMedix in 2021.
  • Hence, increase in investments by key players in developing novel theranostics agents is expected to fuel the growth of the global market

Market Segmentation: Radiopharmaceutical Theranostics Market

  • In terms of radioisotope, the global radiopharmaceutical theranostics market has been classified into technetium-99, gallium-68, iodine-131, iodine-123, fluorine-18, yttrium-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others
  • Based on application, the global radiopharmaceutical theranostics market has been categorized into oncology, cardiology, and others
  • In terms of source, the global radiopharmaceutical theranostics market has been bifurcated into nuclear reactors and cyclotron
  • Based on approach, the global radiopharmaceutical theranostics market has been segregated into targeted therapeutic (Rx) and companion diagnostic (DX)
  • In terms of end user, the global radiopharmaceutical theranostics market has been divided into academic & research institutes, hospitals, and others
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The radiopharmaceutical theranostics market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Regional Overview: Radiopharmaceutical Theranostics Market

  • In terms of region, the global radiopharmaceutical theranostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • North America dominated the global market in 2020. High prevalence of neuroendocrine tumors (NETs) among the population drives the radiopharmaceutical theranostics market in North America. Over 12,000 people in the U.S. are diagnosed with neuroendocrine tumors each year. The sensitivity and specificity of Ga-68 and Lu-177 as a theranostics pair have been evaluated in a number of clinical trials. This factor is expected to fuel the growth of the market in the region. Moreover, well-established healthcare infrastructure and high healthcare spending are likely to augment the radiopharmaceutical theranostics market in North America.
  • The current and expected market revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2021 to 2031, with their CAGRs from 2021 to 2031
  • The study also offers a list of recommendations, highlights, and useful insights of the global radiopharmaceutical theranostics market, which would help new companies willing to enter the market and existing companies to increase market shares and in the decision-making process

Major Players

  • The radiopharmaceutical theranostics market report concludes with the company profiles section, which includes key information about major players in the global radiopharmaceutical theranostics market
  • Leading players analyzed in the report include
    • Nihon Medi-Physics
    • ITM Isotopen Technologien München AG
    • Advanced Accelerator Applications
    • Telix Pharmaceuticals
    • GE Healthcare
    • Theragnostics Ltd.
    • NuView Life Sciences
    • Jubilant Pharma Limited
    • Lantheus Holdings, Inc.
    • Curium Pharma
    • Bayer AG
    • Clarity Pharmaceuticals
  • Each of these players has been profiled in the radiopharmaceutical theranostics market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

Radiopharmaceutical Theranostics Market – Segmentation

TMR’s study on the global radiopharmaceutical theranostics market includes information divided into six segments: radioisotope, application, source, end user, approach, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global radiopharmaceutical theranostics market are discussed in detail.

Radioisotope
  • Technetium-99
  • Gallium-68
  • Iodine-131
  • Iodine-123
  • 18F
  • Y-90
  • Lutetium (Lu) 177
  • Copper (Cu) 67
  • Copper (Cu) 64
  • Others
Application
  • Oncology
  • Cardiology
  • Others
Source
  • Nuclear Reactors
  • Cyclotrons
End User
  • Hospitals
  • Academic & Research Institutes
  • Others
Approach
  • Targeted Therapeutic (Rx)
  • Companion Diagnostic (DX)
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Radiopharmaceutical Theranostics Market Forecast Report, 2021-2031

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of radiopharmaceutical theranostics market?

Radiopharmaceutical theranostics market to reach valuation of US$ 3.9 Bn by 2031

What is the anticipated CAGR of the radiopharmaceutical theranostics market in the forecast period?

Radiopharmaceutical theranostics market is projected to expand at a CAGR of 11% from 2021 to 2031

What are the key driving factors for the growth of the radiopharmaceutical theranostics market?

Radiopharmaceutical theranostics market is driven by increase in therapeutic applications, public awareness, usage of hybrid imaging

Which is the rising prominent segment in the radiopharmaceutical theranostics market?

The lutetium (Lu) 177 segment dominated the global radiopharmaceutical theranostics market in 2020 and the trend is anticipated to continue during the forecast period

Who are the key players in the global radiopharmaceutical theranostics market?

Key players operating in the global market include Nihon Medi-Physics, ITM Isotopen Technologien München AG, Advanced Accelerator Applications, Telix Pharmaceuticals, GE Healthcare

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Radiopharmaceutical Theranostics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Radioisotope Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Overview of Radiopharmaceuticals market

    5.2. FDA Approved Radiopharmaceuticals Products

    5.3. Overview of Radiopharamceutical Diagnostic Market

    5.4. Overview of Radiopharamceutical Therapy Market

    5.5. Regulatory Scenario

    5.6. Current and Future Radiopharmaceutical Theranostics Pairs

    5.7. COVID-19 Impact Analysis

6. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radioisotope

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Radioisotope, 2017–2031

        6.3.1. Technetium-99

        6.3.2. Gallium-68

        6.3.3. Iodine-131

        6.3.4. Iodine-123

        6.3.5. 18F

        6.3.6. Y-90

        6.3.7. Lutetium (Lu) 177

        6.3.8. Copper (Cu) 67

        6.3.9. Copper (Cu) 64

        6.3.10. Others

    6.4. Market Attractiveness Analysis, by Radioisotope

7. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Application, 2017–2031

        7.3.1. Oncology

        7.3.2. Cardiology

        7.3.3. Others

    7.4. Market Attractiveness Analysis, by Application

8. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Source

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Source, 2017–2031

        8.3.1. Nuclear Reactors

        8.3.2. Cyclotrons

    8.4. Market Attractiveness Analysis, by Source

9. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Approach

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Approach, 2017–2031

        9.3.1. Targeted Therapeutic (Rx)

        9.3.2. Companion Diagnostic (DX)

    9.4. Market Attractiveness Analysis, by Approach

10. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by End-user

    10.1. Introduction & Definition

    10.2. Key Findings / Developments

    10.3. Market Value Forecast, by End-user, 2017–2031

        10.3.1. Hospitals

        10.3.2. Academic & Research Institutes

        10.3.3. Others

    10.4. Market Attractiveness Analysis, by End-user

11. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Region

    11.1. Key Findings

    11.2. Market Value Forecast, by Region

        11.2.1. North America

        11.2.2. Europe

        11.2.3. Asia Pacific

        11.2.4. Latin America

        11.2.5. Middle East & Africa

    11.3. Market Attractiveness Analysis, by Country/Region

12. North America Radiopharmaceutical Theranostics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Radioisotope, 2017–2031

        12.2.1. Technetium-99

        12.2.2. Gallium-68

        12.2.3. Iodine-131

        12.2.4. Iodine-123

        12.2.5. 18F

        12.2.6. Y-90

        12.2.7. Lutetium (Lu) 177

        12.2.8. Copper (Cu) 67

        12.2.9. Copper (Cu) 64

        12.2.10. Others

    12.3. Market Value Forecast, by Application, 2017–2031

        12.3.1. Oncology

        12.3.2. Cardiology

        12.3.3. Others

    12.4. Market Value Forecast, by Source, 2017–2031

        12.4.1. Nuclear Reactors

        12.4.2. Cyclotrons

    12.5. Market Value Forecast, by Approach, 2017–2031

        12.5.1. Targeted Therapeutic (Rx)

        12.5.2. Companion Diagnostic (DX)

    12.6. Market Value Forecast, by End-user, 2017–2031

        12.6.1. Hospitals

        12.6.2. Academic & Research Institutes

        12.6.3. Others

    12.7. Market Value Forecast, by Country, 2017–2031

        12.7.1. U.S.

        12.7.2. Canada

    12.8. Market Attractiveness Analysis

        12.8.1. By Radioisotope

        12.8.2. By Application

        12.8.3. By Source

        12.8.4. By Approach

        12.8.5. By End-user

        12.8.6. By Country

13. Europe Radiopharmaceutical Theranostics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Radioisotope, 2017–2031

        13.2.1. Technetium-99

        13.2.2. Gallium-68

        13.2.3. Iodine-131

        13.2.4. Iodine-123

        13.2.5. 18F

        13.2.6. Y-90

        13.2.7. Lutetium (Lu) 177

        13.2.8. Copper (Cu) 67

        13.2.9. Copper (Cu) 64

        13.2.10. Others

    13.3. Market Value Forecast, by Application, 2017–2031

        13.3.1. Oncology

        13.3.2. Cardiology

        13.3.3. Others

    13.4. Market Value Forecast, by Source, 2017–2031

        13.4.1. Nuclear Reactors

        13.4.2. Cyclotrons

    13.5. Market Value Forecast, by Approach, 2017–2031

        13.5.1. Targeted Therapeutic (Rx)

        13.5.2. Companion Diagnostic (DX)

    13.6. Market Value Forecast, by End-user, 2017–2031

        13.6.1. Hospitals

        13.6.2. Academic & Research Institutes

        13.6.3. Others

    13.7. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.7.1. Germany

        13.7.2. U.K.

        13.7.3. France

        13.7.4. Italy

        13.7.5. Spain

        13.7.6. Rest of Europe

    13.8. Market Attractiveness Analysis

        13.8.1. By Radioisotope

        13.8.2. By Application

        13.8.3. By Source

        13.8.4. By Approach

        13.8.5. By End-user

        13.8.6. By Country/Sub-region

14. Asia Pacific Radiopharmaceutical Theranostics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Radioisotope, 2017–2031

        14.2.1. Technetium-99

        14.2.2. Gallium-68

        14.2.3. Iodine-131

        14.2.4. Iodine-123

        14.2.5. 18F

        14.2.6. Y-90

        14.2.7. Lutetium (Lu) 177

        14.2.8. Copper (Cu) 67

        14.2.9. Copper (Cu) 64

        14.2.10. Others

    14.3. Market Value Forecast, by Application, 2017–2031

        14.3.1. Oncology

        14.3.2. Cardiology

        14.3.3. Others

    14.4. Market Value Forecast, by Source, 2017–2031

        14.4.1. Nuclear Reactors

        14.4.2. Cyclotrons

    14.5. Market Value Forecast, by Approach, 2017–2031

        14.5.1. Targeted Therapeutic (Rx)

        14.5.2. Companion Diagnostic (DX)

    14.6. Market Value Forecast, by End-user, 2017–2031

        14.6.1. Hospitals

        14.6.2. Academic & Research Institutes

        14.6.3. Others

    14.7. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.7.1. Japan

        14.7.2. China

        14.7.3. India

        14.7.4. Australia & New Zealand

        14.7.5. Rest of Asia Pacific

    14.8. Market Attractiveness Analysis

        14.8.1. By Radioisotope

        14.8.2. By Application

        14.8.3. By Source

        14.8.4. By Approach

        14.8.5. By End-user

        14.8.6. By Country/Sub-region

15. Latin America Radiopharmaceutical Theranostics Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast By Radioisotope, 2017–2031

        15.2.1. Technetium-99

        15.2.2. Gallium-68

        15.2.3. Iodine-131

        15.2.4. Iodine-123

        15.2.5. 18F

        15.2.6. Y-90

        15.2.7. Lutetium (Lu) 177

        15.2.8. Copper (Cu) 67

        15.2.9. Copper (Cu) 64

        15.2.10. Others

    15.3. Market Value Forecast, by Application, 2017–2031

        15.3.1. Oncology

        15.3.2. Cardiology

        15.3.3. Others

    15.4. Market Value Forecast, by Source, 2017–2031

        15.4.1. Nuclear Reactors

        15.4.2. Cyclotrons

    15.5. Market Value Forecast, by Approach, 2017–2031

        15.5.1. Targeted Therapeutic (Rx)

        15.5.2. Companion Diagnostic (DX)

    15.6. Market Value Forecast, by End-user, 2017–2031

        15.6.1. Hospitals

        15.6.2. Academic & Research Institutes

        15.6.3. Others

    15.7. Market Value Forecast, by Country/Sub-region, 2017–2031

        15.7.1. Brazil

        15.7.2. Mexico

        15.7.3. Rest of Latin America

    15.8. Market Attractiveness Analysis

        15.8.1. By Radioisotope

        15.8.2. By Application

        15.8.3. By Source

        15.8.4. By Approach

        15.8.5. By End-user

        15.8.6. By Country/Sub-region

16. Middle East & Africa Radiopharmaceutical Theranostics Market Analysis and Forecast

    16.1. Introduction

        16.1.1. Key Findings

    16.2. Market Value Forecast, by Radioisotope, 2017–2031

        16.2.1. Technetium-99

        16.2.2. Gallium-68

        16.2.3. Iodine-131

        16.2.4. Iodine-123

        16.2.5. 18F

        16.2.6. Y-90

        16.2.7. Lutetium (Lu) 177

        16.2.8. Copper (Cu) 67

        16.2.9. Copper (Cu) 64

        16.2.10. Others

    16.3. Market Value Forecast, by Application, 2017–2031

        16.3.1. Oncology

        16.3.2. Cardiology

        16.3.3. Others

    16.4. Market Value Forecast, by Source, 2017–2031

        16.4.1. Nuclear Reactors

        16.4.2. Cyclotrons

    16.5. Market Value Forecast, by Approach, 2017–2031

        16.5.1. Targeted Therapeutic (Rx)

        16.5.2. Companion Diagnostic (DX)

    16.6. Market Value Forecast, by End-user, 2017–2031

        16.6.1. Hospitals

        16.6.2. Academic & Research Institutes

        16.6.3. Others

    16.7. Market Value Forecast, by Country/Sub-region, 2017–2031

        16.7.1. GCC Countries

        16.7.2. South Africa

        16.7.3. Rest of Middle East & Africa

    16.8. Market Attractiveness Analysis

        16.8.1. By Radioisotope

        16.8.2. By Application

        16.8.3. By Source

        16.8.4. By Approach

        16.8.5. By End-user

        16.8.6. By Country/Sub-region

17. Competition Landscape

    17.1. Market Player - Competition Matrix (by tier and size of companies)

    17.2. Company Profiles

        17.2.1. Nihon Medi-Physics

            17.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.2.1.2. Company Financials

            17.2.1.3. Growth Strategies

            17.2.1.4. SWOT Analysis

        17.2.2. ITM Isotopen Technologien München AG

            17.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.2.2.2. Company Financials

            17.2.2.3. Growth Strategies

            17.2.2.4. SWOT Analysis

        17.2.3. Advanced Accelerator Applications

            17.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.2.3.2. Company Financials

            17.2.3.3. Growth Strategies

            17.2.3.4. SWOT Analysis

        17.2.4. Telix Pharmaceuticals

            17.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.2.4.2. Company Financials

            17.2.4.3. Growth Strategies

            17.2.4.4. SWOT Analysis

        17.2.5. GE Healthcare

            17.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.2.5.2. Company Financials

            17.2.5.3. Growth Strategies

            17.2.5.4. SWOT Analysis

        17.2.6. Theragnostics Ltd

            17.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.2.6.2. Company Financials

            17.2.6.3. Growth Strategies

            17.2.6.4. SWOT Analysis

        17.2.7. NuView Life Sciences

            17.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.2.7.2. Company Financials

            17.2.7.3. Growth Strategies

            17.2.7.4. SWOT Analysis

        17.2.8. Jubilant Pharma Limited

            17.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.2.8.2. Company Financials

            17.2.8.3. Growth Strategies

            17.2.8.4. SWOT Analysis

        17.2.9. Lantheus Holdings, Inc.

            17.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.2.9.2. Company Financials

            17.2.9.3. Growth Strategies

            17.2.9.4. SWOT Analysis

        17.2.10. Curium Pharma

            17.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.2.10.2. Company Financials

            17.2.10.3. Growth Strategies

            17.2.10.4. SWOT Analysis

        17.2.11. Bayer AG

            17.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.2.11.2. Company Financials

            17.2.11.3. Growth Strategies

            17.2.11.4. SWOT Analysis

        17.2.12. Clarity Pharmaceuticals

            17.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.2.12.2. Company Financials

            17.2.12.3. Growth Strategies

            17.2.12.4. SWOT Analysis

List of Tables

Table 01: FDA Approved Radiopharmaceuticals Products

Table 02: FDA Approved Radiopharmaceuticals Products

Table 03: FDA Approved Radiopharmaceuticals Products

Table 04: Radiopharmaceuticals used in diagnostic applications along with their important physical properties

Table 05: Radiopharmaceuticals used in therapeutic applications along with their important physical properties

Table 06: List of Current and Future Radiopharmaceutical Theranostics Pairs

Table 07: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 08: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

Table 09: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031

Table 10: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031

Table 11: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 13: North America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 14: North America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 15: North America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

Table 16: North America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031

Table 17: North America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031

Table 18: North America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 19: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 20: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 21: Europe Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

Table 22: Europe Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031

Table 23: Europe Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031

Table 24: Europe Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 25: Asia Pacific Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 26: Asia Pacific Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 27: Asia Pacific Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

Table 28: Asia Pacific Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031

Table 29: Asia Pacific Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031

Table 30: Asia Pacific Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 31: Latin America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 32: Latin America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 33: Latin America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

Table 34: Latin America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031

Table 35: Latin America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031

Table 36: Latin America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 37: Middle East & Africa Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 38: Middle East & Africa Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 39: Middle East & Africa Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

Table 40: Middle East & Africa Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031

Table 41: Middle East & Africa Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031

Table 42: Middle East & Africa Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 02: Global Radiopharmaceutical Theranostics Market Value Share, by Region, 2020

Figure 03: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2020 and 2031

Figure 04: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Radioisotope, 2021–2031

Figure 05: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Technetium-99, 2017–2031

Figure 06: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Gallium-68 , 2017–2031

Figure 07: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Iodine-131, 2017–2031

Figure 08: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Iodine-123, 2017–2031

Figure 09: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by 18F , 2017–2031

Figure 10: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Y-90, 2017–2031

Figure 11: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Lutetium (Lu) 177, 2017–2031

Figure 12: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Copper (Cu) 67, 2017–2031

Figure 13: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Copper (Cu) 64, 2017–2031

Figure 14: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017–2031

Figure 15: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2020 and 2031

Figure 16: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Application, 2021–2031

Figure 17: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Oncology, 2017–2031

Figure 18: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Cardiology, 2017–2031

Figure 19: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017–2031

Figure 20: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2020 and 2031

Figure 21: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Source, 2021–2031

Figure 22: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Nuclear Reactors, 2017–2031

Figure 23: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Cyclotrons, 2017–2031

Figure 24: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2020 and 2031

Figure 25: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Approach, 2021–2031

Figure 26: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Targeted Therapeutic (Rx), 2017–2031

Figure 27: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Companion Diagnostic (DX), 2017–2031

Figure 28: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2020 and 2031

Figure 29: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by End-user, 2021–2031

Figure 30: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Hospitals, 2017–2031

Figure 31: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Academic & Research Institutes, 2017–2031

Figure 32: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017–2031

Figure 33: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Region, 2020 and 2031

Figure 34: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Region, 2021–2031

Figure 35: North America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, 2017–2031

Figure 36: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by Country, 2020 and 2031

Figure 37: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country, 2021–2031

Figure 38: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2020 and 2031

Figure 39: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Radioisotope, 2021–2031

Figure 40: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2020 and 2031

Figure 41: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Application, 2021–2031

Figure 42: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2020 and 2031

Figure 43: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Source, 2021–2031

Figure 44: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2020 and 2031

Figure 45: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Approach, 2021–2031

Figure 46: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2020 and 2031

Figure 47: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by End-user, 2021–2031

Figure 48: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, 2017–2031

Figure 49: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 50: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 51: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2020 and 2031

Figure 52: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Radioisotope, 2021–2031

Figure 53: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2020 and 2031

Figure 54: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Application, 2021–2031

Figure 55: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2020 and 2031

Figure 56: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Source, 2021–2031

Figure 57: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2020 and 2031

Figure 58: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Approach, 2021–2031

Figure 59: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2020 and 2031

Figure 60: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by End-user, 2021–2031

Figure 61: Asia Pacific Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, 2017–2031

Figure 62: Asia Pacific Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 63: Asia Pacific Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 64: Asia Pacific Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2020 and 2031

Figure 65: Asia Pacific Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Radioisotope, 2021–2031

Figure 66: Asia Pacific Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2020 and 2031

Figure 67: Asia Pacific Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Application, 2021–2031

Figure 68: Asia Pacific Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2020 and 2031

Figure 69: Asia Pacific Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Source, 2021–2031

Figure 70: Asia Pacific Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2020 and 2031

Figure 71: Asia Pacific Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Approach, 2021–2031

Figure 72: Asia Pacific Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2020 and 2031

Figure 73: Asia Pacific Radiopharmaceutical Theranostics Market Attractiveness Analysis, by End-user, 2021–2031

Figure 74: Latin America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, 2017–2031

Figure 75: Latin America Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 76: Latin America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 77: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2020 and 2031

Figure 78: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Radioisotope, 2021–2031

Figure 79: Latin America Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2020 and 2031

Figure 80: Latin America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Application, 2021–2031

Figure 81: Latin America Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2020 and 2031

Figure 82: Latin America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Source, 2021–2031

Figure 83: Latin America Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2020 and 2031

Figure 84: Latin America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Approach, 2021–2031

Figure 85: Latin America Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2020 and 2031

Figure 86: Latin America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by End-user, 2021–2031

Figure 87: Middle East & Africa Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, 2017–2031

Figure 88: Middle East & Africa Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 89: Middle East & Africa Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 90: Middle East & Africa Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2020 and 2031

Figure 91: Middle East & Africa Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Radioisotope, 2021–2031

Figure 92: Middle East & Africa Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2020 and 2031

Figure 93: Middle East & Africa Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Application, 2021–2031

Figure 94: Middle East & Africa Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2020 and 2031

Figure 95: Middle East & Africa Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Source, 2021–2031

Figure 96: Middle East & Africa Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2020 and 2031

Figure 97: Middle East & Africa Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Approach, 2021–2031

Figure 98: Middle East & Africa Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2020 and 2031

Figure 99: Middle East & Africa Radiopharmaceutical Theranostics Market Attractiveness Analysis, by End-user, 2021–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

1000

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved